Table 2 Population demographic and clinical characteristics for female sub-cohorts
|  |  | LUTS (including OAB) N = 29,094 | SUI N = 1688 |
|---|---|---|---|
Age at index date | n | 29,094 | 1688 |
| Â | Mean (SD) | 62.92 (16.77) | 54.24 (16.29) |
|  | 18–24 | 604 (2.1%) | 32 (1.9%) |
|  | 25–34 | 1121 (3.9%) | 159 (9.4%) |
|  | 35–44 | 2536 (8.7%) | 315 (18.7%) |
|  | 45–54 | 4835 (16.6%) | 399 (23.6%) |
|  | 55–64 | 5264 (18.1%) | 315 (18.7%) |
|  | 65–74 | 6446 (22.2%) | 248 (14.7%) |
|  | ≥ 75 | 8288 (28.5%) | 220 (13.0%) |
Index of multiple deprivation at index prescription (GP surgery level) | n | 11,999 | 665 |
|  | 1 = least deprived | 1534 (12.8%) | 86 (12.9%) |
| Â | 2 | 2418 (20.2%) | 148 (22.3%) |
| Â | 3 | 2292 (19.1%) | 137 (20.6%) |
| Â | 4 | 2285 (19.0%) | 105 (15.8%) |
|  | 5 = most deprived | 3470 (28.9%) | 189 (28.4%) |
New comorbidities | n | 29,094 | 1688 |
Count of newly diagnosed chronic diseases from the QOF within the 12-month pre-index period | Mean (SD) | 0.20 (0.48) | 0.23 (0.53) |
| Â | 0 | 24,327 (83.6%) | 1374 (81.4%) |
| Â | 1 | 3950 (13.6%) | 248 (14.7%) |
| Â | 2 | 712 (2.4%) | 56 (3.3%) |
| Â | 3+ | 105 (0.4%) | 10 (0.6%) |
Polypharmacy | n | 29,094 | 1688 |
Number of distinct BNF headers within the 12-month pre-index period | Mean (SD) | 10.77 (7.49) | 11.55 (7.42) |
| Â | 0 | 681 (2.3%) | 29 (1.7%) |
| Â | [1; 3] | 3766 (12.9%) | 165 (9.8%) |
| Â | [4; 7] | 6944 (23.9%) | 384 (22.7%) |
| Â | [8; 19] | 14,178 (48.7%) | 873 (51.7%) |
| Â | 20+ | 3525 (12.1%) | 237 (14.0%) |
Antimuscarinic treatment experience within the 12-month pre-index period | n | 29,094 | 1688 |
| Â | Yes | 2681 (9.2%) | 56 (3.3%) |
| Â | No | 26,413 (90.8%) | 1632 (96.7%) |